Halozyme Therapeutics

The Patent Trial and Appeal Board has instituted a patent grant review (PGR) against Halozyme Therapeutics amid an ongoing patent infringement lawsuit with Merck & Co.

The global smart drug delivery systems market reached $12 billion in 2024 and is projected to grow at a CAGR of 17% through 2034, driven by rising chronic disease prevalence and technological advancements.

The FDA has approved a new pre-filled syringe formulation of efgartigimod (VYVGART Hytrulo) for self-injection in adults with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

The needle-free injection system market is projected to grow at a CAGR of 4% from $606 million in 2024 to 2035, driven by increasing chronic disease prevalence and patient preference for painless administration.

Better Choice Company has signed a binding Letter of Intent to acquire Choice Specialty Pharmacy Group for approximately 6X its FY2024 Adjusted EBITDA of $4.68 million, to be paid in stock and cash.

Halozyme Therapeutics and Merck are heading into a patent battle over the development of an injectable formulation of the blockbuster cancer drug Keytruda.

Better Choice Company has secured an $8.1 million deal to sell its Halo pet food business in Asia to CZC Company LTD, including $6.5 million in cash and guaranteed royalty payments.

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous use, offering a new administration option for various solid tumors.

Japan's MHLW has approved VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

• Halozyme withdrew its $2.1 billion offer to acquire Evotec after the latter declined to engage in acquisition talks, despite Halozyme's repeated attempts to initiate discussions. • A patient in Neurogene's Rett syndrome gene therapy trial died due to complications from a hyperinflammatory syndrome, a known risk associated with AAV-delivered gene therapies. • Argenx is advancing its efgartigimod program into Phase 2/3 trials for myositis subtypes after positive Phase 2 results showing significant patient improvement compared to placebo. • Kyowa Kirin is paying Kura Oncology $330 million upfront for rights to ziftomenib, an experimental oral leukemia drug, with potential for $420 million more upon market approval.